Share on StockTwits

Ophthotech Corp (NASDAQ:OPHT) CFO Bruce Peacock unloaded 7,739 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $41.07, for a total value of $317,840.73. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of research firms have recently commented on OPHT. Analysts at Morgan Stanley raised their price target on shares of Ophthotech Corp from $79.00 to $99.00 in a research note on Tuesday, May 20th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Ophthotech Corp from $40.00 to $51.00 in a research note on Tuesday, May 20th. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Ophthotech Corp from $55.00 to $58.00 in a research note on Tuesday, May 20th. They now have a “buy” rating on the stock.

Shares of Ophthotech Corp (NASDAQ:OPHT) traded down 0.26% during mid-day trading on Thursday, hitting $40.925. The stock had a trading volume of 55,108 shares. Ophthotech Corp has a one year low of $22.61 and a one year high of $47.99. The stock has a 50-day moving average of $40.72 and a 200-day moving average of $35.06. The company’s market cap is $1.364 billion.

Ophthotech Corp (NASDAQ:OPHT) last announced its earnings results on Tuesday, May 13th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.03. On average, analysts predict that Ophthotech Corp will post $-2.11 earnings per share for the current fiscal year.

Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.